Last reviewed · How we verify

Apsen Farmaceutica S.A. — Portfolio Competitive Intelligence Brief

Apsen Farmaceutica S.A. pipeline: 1 marketed, 0 filed, 2 Phase 3, 7 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 2 Phase 3 7 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Tramal® Tramal® marketed Synthetic opioid analgesic Mu opioid receptor; norepinephrine transporter; serotonin transporter Pain Management
Toragesic® Toragesic® phase 3 NSAID COX-2 Pain management
APSCTC APSCTC phase 3 SGLT2 inhibitor SGLT2 Diabetes

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Pfizer · 2 shared drug classes
  2. Allergan · 2 shared drug classes
  3. AstraZeneca · 2 shared drug classes
  4. Novartis · 2 shared drug classes
  5. Strategic Science & Technologies, LLC · 2 shared drug classes
  6. Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
  7. AceLink Therapeutics, Inc. · 1 shared drug class
  8. AJU Pharm Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Apsen Farmaceutica S.A.:

Cite this brief

Drug Landscape (2026). Apsen Farmaceutica S.A. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/apsen-farmaceutica-s-a. Accessed 2026-05-16.

Related